IL-BRAINLAB
19.5.2022 12:03:05 CEST | Business Wire | Press release
Brainlab announced today that clinicians at UZ Brussel are the first to treat patients with the company’s new Deep Inspiration Breath Hold (DIBH)* technology designed to streamline image guided and surface guided radiation therapy (IGRT and SGRT) and deliver the highest quality of care for breast cancer patients. UZ Brussel is a university hospital at the Vrije Universiteit Brussel with 721 hospital beds and almost 4,000 employees. UZ Brussel successfully validated the technology and presented research at the Novalis Circle Symposium at ESTRO on May 8, 2022. The research demonstrates that Brainlab ExacTrac Dynamic® DIBH streamlines the process and increases positioning confidence through “on-the-fly” X-Ray confirmation. Internal anatomy verification at the breath hold level may increase confidence in dose sparing of critical structures like the heart.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005985/en/
Deep Inspiration Breath Hold is a well-established technique and standard of care in treating breast cancer with radiation therapy. When a patient takes a deep breath, the distance between the heart and the chest cavity is increased, reducing the risk of cardiac toxicity during breast cancer treatment. The new Brainlab technology takes traditional surface tracking methodology and augments it with a thermal signature, delivering a fourth dimension to reduce ambiguities otherwise associated with surface tracking systems. Adding synchronized X-ray images to the workflow increases accuracy and clinician confidence by incorporating insights derived from internal bony anatomy. Brainlab DIBH workflow is CE marked and FDA cleared.
“The incorporation of ‘on-the-fly’ X-Ray confirmation streamlines the process and delivers the confidence that the heart is outside of the treatment beam,” said Stefan Vilsmeier, President and CEO, Brainlab. “This solution delivers correlation between internal and external anatomy in one shot, revealing any misalignment that would otherwise remain undetected and could result in delivering excess dose to the heart. Partnering with UZ Brussel on new technologies demonstrates our combined interest in expanding personalized digital treatment innovation to other indications requiring high precision radiotherapy.”
“This is next generation technology and UZ Brussel is proud to work in close collaboration with our long-time partner Brainlab to validate and present our findings showing the superior speed, innovative postural patient positioning and seamless integration into our therapeutic radiation program,” said Prof. Mark de Ridder, Head of the Radiotherapy Department at UZ Brussel. “We’re excited to be the first to use this game changing positioning and breath hold control in breast cancer patients without skin marks. The positive effect on reducing cardiotoxicity on population level is significant. This becomes even more important with the increasing incorporation of neo-adjuvant chemotherapy and new HER2-directed monoclonal antibodies in the treatment strategy.”
In 2020, Brainlab installed new ExacTrac Dynamic Patient Positioning and Monitoring systems at UZ Brussel. The system’s deep integration with most linear accelerators enables thermal-surface triggered beam gating and repositioning. ExacTrac IGRT has always been the gold standard in frameless cranial, and high-precision spine stereotactic radiosurgery, enabling ablative treatments with minimal target margins.
With the introduction of the DIBH workflow , Brainlab is delivering the power of integrated IGRT to radiation therapy treatments for breast cancer patients. “We implemented this new workflow over the course of a few days,” explained Prof. Thierry Gevaert, Coordinator of the Medical Physics Radiotherapy Department at UZ Brussel. “The use of surface guided technology generates a more stable breathing curve compared to traditional surrogate marker technology. And the system’s X-Ray imaging allows for fast and low-dose internal anatomy verification at breath hold. The accurate triggering and correlation of anatomical verification with ExacTrac kV imaging will be the key differentiator to further margin reduction in breast radiotherapy.”
Please access the Dr. de Ridder presentation here and the Dr. Gevaert presentation here .
*Not yet commercially available in all countries. Please contact your sales representative.
About Brainlab
Brainlab is a digital medical technology pioneer founded in 1989 and headquartered in Munich. The company employs more than 2000 people in 25 locations around the globe. Brainlab serves physicians, medical professionals and their patients in over 6000 hospitals in 121 countries.
Brainlab creates software-driven medical solutions that digitize, automate and optimize clinical workflows for neurosurgery, spine, trauma, craniomaxillofacial (CMF), general and vascular surgery as well as radiotherapy and radiosurgery. Core products center around surgical navigation, radiotherapy, digital operating room integration, and information and knowledge exchange. The Brainlab open framework operating system will allow third parties to develop medical applications to further advance the field of spatial computing and mixed reality.
Brainlab is dedicated to creating an impact in healthcare. The company connects opportunities from emerging digital technologies to transform healthcare at scale and help improve the lives of patients worldwide. For more information, please visit Brainlab and follow on LinkedIn , Twitter , Facebook and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005985/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FuriosaAI Secures $620 Million Series D to Meet Surging Enterprise AI Inference Demand and Accelerate Next-Gen Silicon29.10.2026 00:57:00 CET | Press release
Global investors, including Infinitum, Jericho Capital, QUDA Capital, Cisco Investments, and Worldline Capital, join the round alongside the National Growth Fund of Korea and Korean institutions. FuriosaAI, an AI semiconductor company building sustainable, high-performance inference compute for data centers, today announced the completion of its $620 million (KRW 820 billion) Series D round, bringing its post-money valuation to approximately $2.9 billion. The financing marks a major milestone as FuriosaAI scales global commercial deployments of its RNGD AI inference accelerator. FuriosaAI will use the new capital to expand RNGD production, strengthen its software ecosystem, and accelerate development of its third-generation AI accelerator. International investors contributed a total of $110 million to the round, bringing deep expertise across AI semiconductors and computing infrastructure. U.S.-based Infinitum, an investment firm with extensive experience in the AI semiconductor sector
IFF Declares Dividend for Fourth Quarter 202628.10.2026 21:15:00 CET | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on January 13, 2027 to shareholders of record as of December 19, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20261028159928/en/
Andersen Consulting indgår samarbejde med JKIT28.10.2026 19:57:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital og forretningsmæssig transformation gennem en samarbejdsaftale med John Keells IT (JKIT), en udbyder af teknologiløsninger med base i Sri Lanka. JKIT leverer teknologirådgivning og digitale transformationstjenester til organisationer på tværs af flere brancher, herunder luftfart, finansielle tjenesteydelser, sundhedsvæsen, produktion, detailhandel og telekommunikation. Virksomhedens kompetencer spænder over forretningskritiske applikationer, cloudtransformation, cybersikkerhed, data og analyse, kunstig intelligens samt intelligent automatisering. Gennm strategiske partnerskaber med førende teknologiudbydere som SAP, Microsoft, Salesforce, Databricks og AWS hjælper JKIT organisationer med at modernisere deres teknologiske infrastruktur, effektivisere driften, styrke beslutningsgrundlaget og skabe vækst i forretningen. "Organisationer ønsker i dag at fremskynde deres digitale transformation og ai-tilpasning og har brug for ko
Transition Industries Signs Definitive EPC Agreement with Siemens Energy and Techint E&C for Pacifico Mexinol’s 210 MW Electrolyzer Facility28.10.2026 19:36:00 CET | Press release
Definitive agreement advances delivery of the electrolyzer facility supplying renewable hydrogen for ultra-low-carbon methanol production in Sinaloa, Mexico Transition Industries LLC today announced that it has signed a definitive Engineering, Procurement and Construction (EPC) agreement with Siemens Energy and Techint Engineering & Construction (“Techint E&C”) for the approximately 210 MW electrolyzer facility at its Pacifico Mexinol project in Sinaloa, Mexico. The agreement is subject to customary conditions precedent, including the completion of project financing. The signing builds on the Front-End Engineering Design (FEED) contract announced in August 2025 and represents an important milestone in advancing the project’s renewable hydrogen production infrastructure from engineering toward construction. The facility will incorporate Siemens Energy’s Elyzer P-300 electrolyzer technology and produce renewable hydrogen to support the production of renewable fuels of non-biological orig
Belkin Introduces Infinity Folio for iPad mini, Available Now28.10.2026 19:21:00 CET | Press release
With a precision-engineered hinge that allows flexible viewing angles, all-around drop protection, and a frosted translucent back panel, Infinity Folio is the perfect companion for iPad mini from day one Belkin, a global leader in consumer electronics accessories trusted by more than 1 billion customers worldwide, today introduced Infinity Folio, a beautifully crafted protective case exclusively designed for iPad mini. The Infinity Folio is engineered to protect without compromise. A thin, lightweight and translucent back lets the new iPad mini design shine through with 360° of protection against drops of up to 2 meters*. The ingeniously engineered detachable cover transforms into a stand with multiple viewing angles. Whether it's streaming a favorite show, joining a video call, or reading an exciting book, Infinity Folio adapts to every moment. Designed specifically for iPad mini, Infinity Folio is available at launch through Apple stores and online in select markets worldwide, with a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
